INTRAPERITONEAL RADIOLOCALIZATION OF TUMORS PRE-TARGETED BY BIOTINYLATED MONOCLONAL-ANTIBODIES

被引:111
作者
PAGANELLI, G
PERVEZ, S
SICCARDI, AG
ROWLINSON, G
DELEIDE, G
CHIOLERIO, F
MALCOVATI, M
SCASSELLATI, GA
EPENETOS, AA
机构
[1] OSPED GEN PROVINCIALE M BUFALINI,I-47023 CESENA,ITALY
[2] HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,ONCOL GRP,LONDON W12 0HS,ENGLAND
[3] UNIV MILAN,DIPARTIMENTO BIOL & GENET SCI MED,I-20122 MILAN,ITALY
[4] SORIN BIOMED SPA,I-13040 SALUGGIA,ITALY
[5] SOC PROD ANTIBIOTICI SPA,MILAN,ITALY
关键词
D O I
10.1002/ijc.2910450632
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We describe 2‐step and 3‐step strategies for intraperitoneal tumor radio‐localization by means of monoclonal antibodies (MAbs). Nude mice bearing intraperitoneal human colon carcinoma tumors were injected i.p. with biotinylated MAb AUAI, followed 24 hr later by radioiodinated streptavidin (2‐step). The uptake of radioactivity in tumor and normal tissues was measured 4 hr after injection of radioactive compound. A 3‐step strategy consisted in administering biotinylated antibody, cold avidin after 24 hr and 111In‐labelled biotin after a further 4 hr; mice were then killed 2 hr later. Tumor localization of intraperitoneally‐administered biotinylated antibody and direct targeting of radioactive streptavidin to biotinylated antibody bound to tumor sites were demonstrated using immunohistochemistry and autoradiography. Our results show that (i) the 2‐step approach increased the percentage of radioactivity uptake by tumor with respect to directly labelled antibodies (24% vs. 6%) and improved the tumor/non‐tumor ratio; (ii) the 3‐step approach allowed faster blood clearance of the radioactive probe (111In‐biotin) and yielded high tumor/non‐tumor ratios. “Pre‐targeting” methods appear to have advantages over the conventional 1‐step approach with directly radiolabelled antibody. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:1184 / 1189
页数:6
相关论文
共 22 条
[1]  
ARKLIE J, 1981, THESI SOXFORD U
[2]   IMAGING OF PRIMARY AND METASTATIC COLORECTAL-CANCER USING AN IN-111-LABELLED ANTITUMOUR MONOCLONAL-ANTIBODY (791T/36) [J].
ARMITAGE, NC ;
PERKINS, AC ;
PIMM, MV ;
WASTIE, ML ;
BALDWIN, RW ;
HARDCASTLE, JD .
NUCLEAR MEDICINE COMMUNICATIONS, 1985, 6 (10) :623-631
[3]   ANTIBODY DIRECTED ENZYMES REVIVE ANTICANCER PRODRUGS CONCEPT [J].
BAGSHAWE, KD .
BRITISH JOURNAL OF CANCER, 1987, 56 (05) :531-532
[4]   USE OF AN ENZYME-LINKED IMMUNOSORBENT-ASSAY FOR SCREENING HYBRIDOMA ANTIBODIES AGAINST HEPATITIS-B SURFACE-ANTIGEN [J].
BONIOLO, A ;
DOVIS, M ;
MATTEJA, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 1982, 49 (01) :1-15
[5]  
BURAGGI GL, 1984, J NUCL MED ALLIED S, V28, P282
[6]   DETECTION OF COLORECTAL-CARCINOMA BY EMISSION-COMPUTERIZED TOMOGRAPHY AFTER INJECTION OF I-123 LABELED FAB OR F(AB')2 FRAGMENTS FROM MONOCLONAL ANTICARCINOEMBRYONIC ANTIGEN ANTIBODIES [J].
DELALOYE, B ;
BISCHOFDELALOYE, A ;
BUCHEGGER, F ;
VONFLIEDNER, V ;
GROB, JP ;
VOLANT, JC ;
PETTAVEL, J ;
MACH, JP .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 77 (01) :301-311
[7]  
DREWINKO B, 1976, CANCER RES, V36, P467
[8]  
EPENETOS AA, 1982, LANCET, V2, P999
[9]   IMPROVED TUMOR-LOCALIZATION USING IN-111 LABELED ANTIBODIES [J].
FAIRWEATHER, DS ;
BRADWELL, AR ;
DYKES, PW ;
VAUGHAN, AT ;
WATSONJAMES, SF ;
CHANDLER, S .
BRITISH MEDICAL JOURNAL, 1983, 287 (6386) :167-170
[10]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219